Preamble
The first international meeting of Medical Advisers in the Pharmaceutical Industry was held in London in April 1972, and published as *International Aspects of Drug Evaluation and Usage* (edited by AJ Jouhar and MF Grayson; Edinburgh: Churchill Livingstone, 1973; see no. (26) above). At the second international meeting, in Florence, detailed here, the society changed its name to the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP). The third international meeting was held in Brussels in 1978 and published as *Pharmaceutical Medicine – the Future* (edited by H Lahon; RK Rondel and C Kratochvil; Brussels: Acta Therapeutica, 1979). The fourth international meeting was held in Paris in April 1981 and published as *Drug Safety – Progress and Controversies* (edited by Michel Auriche, John Burke and Jacques Duchier; Oxford: Pergamon Press, 1982). IFAPP continues to organise international meetings and details can be found on its website (ifapp.org/history-2).

Aims
The second international meeting of the Medical Advisers in the Pharmaceutical Industry took place in Florence from October 12th to 15th, 1975. More than 400 representatives of 29 countries and 83 pharmaceutical companies were present. The first meeting, held in London in 1972 had been conceived as “an attempt to assess the current state of the evaluation and use of drugs throughout the world, as seen through the eyes of medically qualified people working in the pharmaceutical industry. The second meeting went a step further, trying to make the point of the current state of the international cooperation in drug testing. There is now greater interest in international trials: it seems that the elements in common in the results of multi-national trials exceed those which contrast and that the so-called ethnical differences and the differences in therapeutic responses due to the different medical and social cultures, if kept under control by the experimental design, allow an unbiased enlargement of the inference resulting from the experimental data. Increased international cooperation enables one to avoid dispersion of effort in unnecessary duplication and, in the end, leads to a more rapid development of better medicines, which are much in demand in our time. This book is divided into three sections, which correspond to the main sections of the meeting: the first one reviews from a scientific, technical and operational standpoint what was done, what was drawn, what can be developed in the field of clinical trials organized on an international basis. In the second session the Health Authorities of a few representative countries expose their position in regard of data coming from non-national or international studies. In the third section, finally, a selection of papers on current problems in drug research methodology is presented (Preface, page vii).

Contents (xi + 263 pages)
Chairmen
Editors
Preface (PE Lucchelli, N Bergamini, V Bachini)
I. International cooperation in drug testing
   International cooperation in drug testing in a changing world (L Lasagna)
   Hypertension: drug treatment and community control (T Strasser)
   International aspects of teaching medical advisers (C Maxwell)
International cooperative clinical trials and other behavioural sciences (CRB Joyce)
Assessing the safety and efficacy of international trials in psychopathology (J Levine)
International collaboration in different phases of drug research: two practical experiences (V Bachini, N Bergamini, MC Cozzi, A Ferrario, G Fowst, V Patrini, A Trumellini)
Experiences and initiatives of drug evaluation in the field of tuberculosis (L Trnka, J Tousek, P Mison)
International liaison in clinical testing of new anticancer drugs (SK Carter)
The international NDA – USA (SL DeFelice)
Some aspects of international trials of new antibiotics (EAP Croydon)
International monitoring guidelines and managing clinical research (RA Guarino)
An experimental drug monitoring by a pharmaceutical company (V Ferrari)
International aspects of drug testing (TB Binns)

II. Attitude of the national health authorities towards international cooperation in drug testing
Modern drug research – a challenge to health authorities (F Gross)
Acceptance of foreign data by the US Food and Drug Administration (JR Crout)
Developments in the United Kingdom drug regulatory system (MF Cuthbert)
Aspects and prerequisites for the acknowledgement of foreign documents and international trials for drug registration in the Federal Republic of Germany (GM Fülgraff)
Attitude of the Swedish health authorities towards integration of international data in the Swedish system for approval and release of new drugs (A Liljestrand)
Public aspects of drug control (D Poggiolini)
Some aspects of international cooperation in new drugs evaluation (J Elis)
International co-operation in drug testing – conclusions and recommendations

III. Selected topics in drug research methodology
The evaluation of a new medicine in healthy man (WL Burland)
A new screening procedure of drugs on anesthetized dogs: mapping of effects on regional and cardiac hemodynamics by electromagnetic flowmetry (GA Charbon)
Evaluation of a new urinary antibacterial: research methodology (KN Ghatikar)
Art and logistics in international multicentre trials (KG Green)
Use of non-invasive methods in the clinical-pharmacological testing of cardiovascular drugs (L Matos)
The evaluation of oral contraceptives: methods for comparing patterns of the menstrual cycle induced by different agent (JN Sartoretto, R Moraes, JC Ortega-Recio, F Navas Filho)
Difficulties and opportunities for drug testing in South America (JN Sartoretto)
A comparative evaluation of the writhing response induced by aconitine, phenylquinone and bradykinin for the assessment of analgesic agents (JN Sinha, TN Bhalla, RP Kohli, KP Bhargava)
A pan European clinical trial of a broad spectrum antibiotic in respiratory tract infections – its structure and accomplishments (H Swarz, HFJ Lahon)
The use of computer simulated results as an aid to teaching clinical trial methodology (SN Ciccolunghi, CRB Joyce, KG Liebrich)
Distribution kinetics of decaspiride (L Colombo Spirola, V Viganò)
The application of the bioassay for non parametric data to the evaluation of the analgesic activity in man (LM Fuccella, G Corvi, V Mandelli)
Digital analysis of photographic light traces of human gait (Pl Dern, A Grubenmann, NP Maurice, P Mennet, L Ulrych)
Pharmacokinetic analysis of quantitative EEG data (M Fink, P Irwin, M Gastpar)
The pharmaceutical industry and post-registration surveillance of new drugs: 20 years’ experience (JM Frisch)
Side effects of placebo (T Ishioka)
The place of two simulation exercises in the teaching of drug research methodology (BT Marsh)
Drug absorption in malabsorption syndromes (RL Parsons, GM Paddock, CM Kaye)
Collaborative antibiotic studies in academic and industrial clinical pharmacology units (GM Paddock, RL Parsons, DM Vickers, WV Vischer)
Future shock in therapeutics – a challenge to clinical pharmacologists (PK Pispati)
Dose response studies and combined treatment programs with lipid lowering drugs (S Rössner, AG Olsson, L Òro)
Clustering cholinergic receptors by muscarine and muscarone analogues (L Rossini, F Martorana, P Periti)
Clinical pharmacology in a drug development system (TJ Sullivan, PJ Fell)
Design and conduct of clinical experiments performed at more than one location (R Teichman, RJ Bower)
Rational drug evaluation in developing countries (AS Nanivadekar)
Research methodology of digestive enzymes (S Agarwala)
Some observations on the effects of neuromuscular blocking agents administered during the later part of gestation in the rat fetus (AA Shoro)
Carbamazepine in the treatment of acute withdrawal syndrome in alcoholics: methodological aspects (T Sonck, L Malinen, J Jänne)
A kit for an objective assessment of some performance of upper limbs (G Sacchetti, J Parini, E Magni)
Historical fragments of clinical trials (V Ferrari)

Index of authors

Authors
The editors are PE Lucchelli MD (Vice-Chairman, Societá di Scienze Farmacologiche Applicate and Medical Director, Ciba-Geigy SpA, Origgio, Varese, Italy), N Bergamini MD (Director, Therapeutic Research, Carlo Erba SpA, Milano, Italy), and V Bachini MD (Corporate Medical Department, Gruppo Lepetit SpA, Milano, Italy). The contributors are S Agarwala (Chief Medical Adviser, Rallis India Ltd, Bombay, India); TN Bhalla (Department of Pharmacology and Therapeutics, King George’s Medical College, Lucknow, India), KP Bhargava (Department of Pharmacology and Therapeutics, King George’s Medical College, Lucknow, India); TB Binns (London Hospital Medical College, Department of Pharmacology and Therapeutics, London, UK); Robert J Bower (Merck, Sharp and Dohme Research Laboratories, West Point, PA, USA); WL Burland (The Research Institute, Smith Kline and French Laboratories, Welwyn Garden City, England); Stephen K Carter (Deputy Director, Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, USA); GA Charbon (Experimental Laboratory, Department of Thoracic Surgery, University Hospital Utrecht, The Netherlands); SN Ciccolunghi (Medical Department and Wissenschaftliches Rechenzentrum, Ciba-Geigy AG, Basel, Switzerland); L Colombo Spirola (Fardeco SpA Research Centre, Codogno, Milan, Italy); G Corvi (Carlo Erba Research Institute, Milan, Italy); MC Cozzi (Corporate Medical Department, Dow-Lepetit, Milan, Italy), J Richard Crout MD (Federal Drug Administration, Washington DC, USA); EAP Croydon (Beecham Pharmaceuticals International Division, Brentford, Middlesex, England); MF Cuthbert (Medicines Division, Department of Health and Social Security, London, England); Stephen L DeFelice MD (Bio/Basics International Corporation, New York City, NY, USA); PI Dern (Medical Department, Ciba-Geigy Ltd, Basel, and Solbad Clinie, Rheinfelden, Switzerland); J Elis (Department of Clinical Pharmacology, Institute of Pharmacology, Czechoslovak Academy of Sciences, Prague, Czechoslovakia); PJ Fell (Research and Development
Department, Fisons Ltd, Pharmaceutical Division, Loughborough, Leicestershire, UK; V Ferrari MD (Medical Department, Zambon SpA, Bresso, Milan, Italy); A Ferrario (Corporate Medical Department, Dow-Lepetit, Milan, Italy, Max Fink MD (Department of Psychiatry, Health Sciences Center, State University of New York at Stony Brook, Stony Brook, New York, USA); G Fowst (Corporate Medical Department, Dow-Lepetit, Milan, Italy; JM Frisch (The Wellcome Foundation Ltd, London, England); LM Fuccella (Carlo Erba Research Institute, Milan, Italy); GM Fülgraff (Federal Health Office, Berlin, Federal Republic of Germany); Markus Gastpar MD (The Psychiatrische Universitätsklinik, Basle, Switzerland); KN Ghatikar MD (Chief Medical Adviser, Warner-Hindustan Ltd, Bombay, India) KG Green (ICI Ltd, Pharmaceuticals Division, Clinical Research Department, Macclesfield, Cheshire, UK); F Gross (Chairman, Department of Pharmacology, University of Heidelberg, Federal Republic of Germany); A Grubenmann (Medical Department, Ciba-Geigy Ltd, Basel, and Solbad Clinic, Rheinfelden, Switzerland); Richard A Guarino MD (USV Pharmaceutical Corporation, Tuckahoe, New York, USA); Peter Irwin BA (Department of Psychiatry, Health Sciences Center, State University of New York at Stony Brook, Stony Brook, New York, USA); Tadao Ishioka (Toyo Jozo Co Ltd, Tokyo, Japan); J Jänne (Ciba-Geigy Medical Department, Hässle-Ciba-Geigy Oy, Helsinki, Finland); CRB Joyce (Medical Department, Ciba-Geigy Ltd, Basel, Switzerland); CM Kaye (Department of Clinical Pharmacology, St Bartholomew’s Hospital, London, UK); RP Kohli (Department of Pharmacology and Therapeutics, King George’s Medical College, Lucknow, India); Herman FJ Lahon (Medical Department, Pfizer Europe, Brussels, Belgium); L Lasagna (Chairman, Institute of Pharmacology, School of Medicine and Dentistry, Rochester University, Rochester, NY, USA); J Levine (Chief, Psychopharmacology Research Branch, National Institute of Mental Health, Rockville, Maryland, USA); KG Liebrich (Medical Department and Wissenschaftliches Rechenzentrum, Ciba-Geigy AG, Basel, Switzerland); A Liljestrand (Department of Drugs, National Board of Health and Welfare, Stockholm, Sweden); E Magni (Medical Department, Clinical Research Division, Carlo Erba, Milan, Italy); Laila Malinen (Ciba-Geigy Medical Department, Hässle-Ciba-Geigy Oy, Helsinki, Finland); V Mandelli (Carlo Erba Research Institute, Milan, Italy); BT Marsh (Medical Department, Leo Laboratories Ltd, Hayes, Middlesex, England); Franco Martorana (Scuola Normale Superiore, Pisa, Italy); L Matos (Hungarian Institute of Cardiology, Division of Clinical Pharmacology, Budapest, Hungary); NP Maurice (Medical Department, Ciba-Geigy Ltd, Basel, and Solbad Clinic, Rheinfelden, Switzerland); Dr Cyril Maxwell (Clinical Research Services Ltd, London, England); P Mennet (Medical Department, Ciba-Geigy Ltd, Basel, and Solbad Clinic, Rheinfelden, Switzerland); P Mišoň (Research Institute for Tuberculosis and Respiratory Disease, Prague, Czechoslovakia); R Moraes (Department of Clinical Investigation, Indústrias Farmacêuticas Fontoura-Wyth SA, São Paulo, Brazil); AS Nanivadekar (Pfizer Ltd, Bombay, India); F Navas Filho (Department of Clinical Investigation, Indústrias Farmacêuticas Fontoura-Wyth SA, São Paulo, Brazil); AG Olsson (Karolinska Hospital and King Gustaf V Research Institute, Stockholm, Sweden); L Öro (Karolinska Hospital and King Gustaf V Research Institute, Stockholm, Sweden); JCR Ortega-Recio (Department of Clinical Investigation, Indústrias Farmacêuticas Fontoura-Wyth SA, São Paulo, Brazil); GM Paddock (Department of Clinical Pharmacology, Guy’s Hospital Medical School, London, UK); J Parini (Medical Department, Clinical Research Division, Carlo Erba, Milan, Italy); RL Parsons (Department of Clinical Pharmacology, Guy’s Hospital Medical School, London, UK); V Patrini (Corporate Medical Department, Dow-Lepetit, Milan, Italy); Pierfrancesco Periti (Istituto G Golgi of General Pathology, University of Pavia, Italy); PK Pispatai (Medical Adviser, The Boots Company (India and Far East) Ltd, Bombay, India); D Poggioioli (Direzione Generale Servizio Farmaceutico, Ministero della Sanita, Roma, Italy); Luigi Rossini (Laboratory of Pharmacology, Institute of Experimental and
Clinical Medicine, University of Ancona School of Medicine, Ancona, Italy); S Rössner (Karolinska Hospital and King Gustaf V Research Institute, Stockholm, Sweden); G Sacchetti (Medical Department, Clinical Research Division, Carlo Erba, Milan, Italy); JN Sartoretto (Department of Clinical Investigation, Indústrias Farmacêuticas Fontoura-Wyeth SA, São Paulo, Brazil); AA Shoro (Department of Anatomy, St Thomas’s Hospital Medical School, London); JN Sinha (Department of Pharmacology and Therapeutics, King George’s Medical College, Lucknow, India); T Sonck (Ciba-Geigy Medical Department, Hässle-Ciba-Geigy Oy, Helsinki, Finland); T Strasser (Cardiovascular Diseases Unit, World Health Organization, Geneva, Switzerland); TJ Sullivan (Research and Development Department, Fisons Ltd, Pharmaceutical Division, Loughborough, Leicestershire, UK); Herbert Swarz (Medical Department, Pfizer Europe, Brussels, Belgium); Robert Teichman (ICI United States Inc, Wilmington, Delaware, USA); J Toušek (Research Institute for Tuberculosis and Respiratory Disease, Prague, Czechoslovakia); L Trnka (Research Institute for Tuberculosis and Respiratory Disease, Prague, Czechoslovakia); A Trumellini (Corporate Medical Department, Dow-Lepetit, Milan, Italy); L Ulrych (Medical Department, Ciba-Geigy Ltd, Basel, and Solbad Clinic, Rheinfelden, Switzerland); DM Vickers (Department of Microbiology, Abbott Laboratories Ltd, Queenborough, Kent, UK); V Viganò Spirola (Fardeco SpA Research Centre, Codogno, Milan, Italy); and, WV Vischer (Department of Clinical Pharmacology, Guy’s Hospital Medical School, London, UK).